MedPath

Early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome a randomized, placebo-controlled trial evaluating the clinica benefits of early front-loated Eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome EARLY ACS

Conditions
on-ST-segment elevation acute coronary syndrome
Registration Number
EUCTR2004-000120-32-IT
Lead Sponsor
SCHERING-PLOUGH
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
10500
Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: ;Secondary Objective: ;Primary end point(s):
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath